company background image
LLY logo

Eli Lilly NYSE:LLY Stock Report

Last Price

US$829.84

Market Cap

US$732.3b

7D

5.3%

1Y

40.8%

Updated

04 Dec, 2024

Data

Company Financials +

LLY Stock Overview

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. More details

LLY fundamental analysis
Snowflake Score
Valuation3/6
Future Growth5/6
Past Performance4/6
Financial Health3/6
Dividends0/6

Community Narratives

Create a narrative

Narratives bring a range of perspectives from our community.

Eli Lilly and Company Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Eli Lilly
Historical stock prices
Current Share PriceUS$829.84
52 Week HighUS$972.53
52 Week LowUS$561.65
Beta0.40
11 Month Change2.94%
3 Month Change-9.08%
1 Year Change40.83%
33 Year Change239.65%
5 Year Change587.07%
Change since IPO29,446.46%

Recent News & Updates

Recent updates

Lilly's Head-To-Head Data Lands Blow On Novo In Battle For Weight Loss Supremacy

Dec 04

Here's Why Eli Lilly (NYSE:LLY) Can Manage Its Debt Responsibly

Nov 29
Here's Why Eli Lilly (NYSE:LLY) Can Manage Its Debt Responsibly

Eli Lilly: An Early Christmas Present Has Just Arrived (Rating Upgrade)

Nov 28

Eli Lilly Stock: Unexpected Developments (Rating Downgrade)

Nov 21

Eli Lilly and Company Just Missed EPS By 31%: Here's What Analysts Think Will Happen Next

Nov 01
Eli Lilly and Company Just Missed EPS By 31%: Here's What Analysts Think Will Happen Next

Taking A Look At Eli Lilly's Q3 2024 Revenue Miss Amid Supply Chain Challenges

Oct 30

Eli Lilly Buy On Weakness Signal (Technical Analysis)

Oct 20

Eli Lilly: Ebglyss To Challenge Dupixent In Atopic Dermatitis

Sep 30

Eli Lilly: I Admit Defeat As I Understated Its Growth Prospects  (Upgrade)

Sep 20

Eli Lilly (NYSE:LLY) Gains FDA Approval for EBGLYSS, Expands Strategic Alliances for Market Growth

Sep 18
Eli Lilly (NYSE:LLY) Gains FDA Approval for EBGLYSS, Expands Strategic Alliances for Market Growth

Eli Lilly: Zepbound Price Cuts Have Multiple Positives, Limited Downside

Sep 04

Eli Lilly: Tirzepatide's Winning Streak Continues

Aug 20

Eli Lilly Triggers Our Confirmed Buy Signal (Technical Analysis)

Aug 12

Eli Lilly: I Expect Strong Q2 Earnings, But The Valuation Is Already Optimistic

Aug 04

Shareholder Returns

LLYUS PharmaceuticalsUS Market
7D5.3%0.8%0.4%
1Y40.8%12.1%32.3%

Return vs Industry: LLY exceeded the US Pharmaceuticals industry which returned 12.1% over the past year.

Return vs Market: LLY exceeded the US Market which returned 32.3% over the past year.

Price Volatility

Is LLY's price volatile compared to industry and market?
LLY volatility
LLY Average Weekly Movement4.3%
Pharmaceuticals Industry Average Movement10.1%
Market Average Movement6.3%
10% most volatile stocks in US Market16.3%
10% least volatile stocks in US Market3.1%

Stable Share Price: LLY has not had significant price volatility in the past 3 months compared to the US market.

Volatility Over Time: LLY's weekly volatility (4%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
187643,000Dave Rickswww.lilly.com

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio.

Eli Lilly and Company Fundamentals Summary

How do Eli Lilly's earnings and revenue compare to its market cap?
LLY fundamental statistics
Market capUS$732.35b
Earnings (TTM)US$8.37b
Revenue (TTM)US$40.86b

89.3x

P/E Ratio

18.3x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
LLY income statement (TTM)
RevenueUS$40.86b
Cost of RevenueUS$7.80b
Gross ProfitUS$33.06b
Other ExpensesUS$24.69b
EarningsUS$8.37b

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)9.30
Gross Margin80.91%
Net Profit Margin20.48%
Debt/Equity Ratio218.1%

How did LLY perform over the long term?

See historical performance and comparison

Dividends

0.6%

Current Dividend Yield

54%

Payout Ratio

Does LLY pay a reliable dividends?

See LLY dividend history and benchmarks
When do you need to buy LLY by to receive an upcoming dividend?
Eli Lilly dividend dates
Ex Dividend DateNov 15 2024
Dividend Pay DateDec 10 2024
Days until Ex dividend20 days
Days until Dividend pay date5 days

Does LLY pay a reliable dividends?

See LLY dividend history and benchmarks